Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Examining the Role of Sensitivity to Uncertain Threat and Alcohol Response in Risk for Alcohol Use Disorder Following Sexual Assault in College Women

16. november 2026 oppdatert av: Stephanie M Gorka, PhD, Ohio State University

The goal of this clinical trial is to determine whether women who engage in heavy drinking with a history of sexual assault (SA) victimization show heightened baseline reactivity to uncertain threat (U-threat), whether alcohol reduces this reactivity and related anxiety, and how these processes link to real-world drinking behavior. The main questions it aims to answer are:

  • Test whether heavy drinking women with a history of SA display exaggerated baseline reactivity to U-threat.
  • In the lab, test whether alcohol intoxication is associated with decreases in reactivity to U-threat and subjective anxiety, particularly in heavy drinking women with a history of SA.
  • In the real-world, test associations between SA victimization, reactivity to U-threat, alcohol consumption, and anxiolytic relief.

Participants will:

  • Complete a screening and orientation session
  • Complete two experimental lab sessions that will include intravenous (IV) administration of either 80mg% alcohol or placebo (saline), order counterbalanced
  • Complete daily ecological momentary assessments (EMA) surveys for 21 days
  • Wear a transdermal alcohol wrist biosensor (BACTrack Skyn) for 21-days

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

220

Fase

  • Tidlig fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

21 år til 29 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

General Inclusion Criteria for All Participants:

  • Biological female
  • 21-29 years old
  • At least a high school education
  • Fluency in English
  • Heavy drinker as defined as 8 or more alcoholic drinks per week and at least two binge episodes (4 or more drinks for in a 2-hour period) in the past month

Additional Inclusion Criteria for Heavy Drinkers with History of Sexual Assault (HD+SA) Group:

- Self-reported experience of sexual assault victimization after age 14.

Additional Inclusion Criteria for Heavy Drinkers without History of Sexual Assault (HD-SA) Group:

- No exposure to lifetime DSM-5 Criterion A traumatic stressor. Participants will not be excluded for accidents, injuries, or witnessing community violence to ensure the sample is representative.

Exclusion Criteria for All Participants:

  • Any serious medical problems (e.g., liver disease, cardiac abnormality, pancreatitis, diabetes, neurological problems, and gastrointestinal disorders)
  • Body weight < 110 or > 210 lbs
  • Current medical or psychiatric condition requiring medication for which alcohol consumption is contraindicated
  • Substance use disorder other than mild and moderate alcohol use disorder
  • Positive urine screen for drugs other than cannabis
  • Currently seeking or past-12-month history of inpatient or intensive treatment for addictive behaviors
  • Pregnancy, nursing, or planning to become pregnant in the next 3 months
  • Report smoking more than 5 cigarettes (or electronic equivalent) per day
  • Lifetime history of psychosis.

Additional Exclusion Criteria for HD+SA Group:

- Report a first onset SA within the past 30 days

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Annen: Heavy Drinking with a History of Sexual Assault Victimization (HD+SA)

Participants in this group will be required to be biological females between the ages of 21-29 who engage in heavy drinking with a history of sexual assault victimization after age 14.

Participants receive placebo (saline) intravenously.

Participants will receive 80 mg% intravenous alcohol.

Annen: Heavy Drinking without a History of Sexual Assault Victimization (HD-SA)

Participants in this group will be required to be biological females between the ages of 21-29 who engage in heavy drinking either without a history of sexual assault victimization after age 14.

Participants receive placebo (saline) intravenously.

Participants will receive 80 mg% intravenous alcohol.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Startle eyeblink potentiation during the threat task
Tidsramme: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)

Startle eyeblink potentiation will be collected during the NPU threat task that is administered at all three lab sessions. Startle is a cross-species index of aversive reactivity.

Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
Subjective affective response to alcohol in the lab
Tidsramme: At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.

Participants will complete the Profile of Mood States (POMS) throughout the placebo and alcohol administration protocols. The Profile of Mood States Anxiety subscale consists of 9 items, with each item rated from 0 (not at all) to 4 (extremely), resulting in a total score ranging from 0 to 36. Higher scores indicate greater subjective anxiety, while lower scores indicate less subjective anxiety. The Anxiety subscale will serve as the primary measure of subjective anxiety and will be compared between the placebo and alcohol sessions.

At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
Subjective effects of alcohol in the lab
Tidsramme: At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.

Participants will rate the degree to which they 'feel', 'like', and 'want more' of the infused substance on a visual analogue scale ranging from 0 ('not at all') to 100 ('extremely'). The 'like' and 'want more' scales will serve as the primary measures of drug liking and drug wanting, respectively.

At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
Ecological momentary assessment (EMA) of affective response to alcohol in the real world
Tidsramme: Assessed daily for 21-days

Up to five times per day, participants will complete ecological momentary assessments (EMA) of their current anxiety, distress, and other mood states. Participants will rate each emotion on a 0-5 scale, where 0 = not at all and 5 = extremely. Affect will be assessed during periods of sobriety and intoxication.

Assessed daily for 21-days
Transdermal alcohol concentration (TAC)
Tidsramme: Assessed daily for 21-days

Participants' TAC will provide an objective estimate of alcohol consumption.

Assessed daily for 21-days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. november 2026

Primær fullføring (Antatt)

1. august 2031

Studiet fullført (Antatt)

1. august 2031

Datoer for studieregistrering

Først innsendt

16. september 2026

Først innsendt som oppfylte QC-kriteriene

19. oktober 2026

Først lagt ut (Faktiske)

26. oktober 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

19. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 2024H0264
  • 1R01AA032115-01A1 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified data, including startle eyeblink and behavior, from this project will be submitted to the The National Institute on Alcohol Abuse and Alcoholism Data Archive (NIAAADA) at the subject level along with appropriate supporting documentation to enable efficient use of the data by the research community. We will follow instructions as discussed in the NDA Data Sharing Terms and Conditions.

IPD-delingstidsramme

The data will be submitted biannually.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .